Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD

Completed · Phase 2 · Has a placebo group

Conditions studied: Anhedonia, Major Depressive Disorder

In brief

To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).

Key facts

Study ID
NCT05165394
Run by
Neurocrine Biosciences
People needed
93
Starts
2021-11-30
Expected to finish
2023-09-13
Last updated by the study team
2024-07-31

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.